At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 29 enrolled
Drug / intervention
Pneumovax 23- pneumococcal polysaccharide +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Vaccine Effectiveness and Seroconversion to 23 Valent Pneumococcal Polysaccharide Vaccination in Children With Type 1 Diabetes
In Brief
A Phase 4 clinical trial evaluating Pneumovax 23- pneumococcal polysaccharide and Blood draw for Type 1 Diabetes. Completed, enrolled 29 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if children with type 1 diabetes have adequate immune response to PPSV23 vaccination and to assess factors affecting immune response.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartApr 2021
Primary CompletionJan 2023
TodayJul 2026
First PostedJul 22, 2020
Enrollment StartApr 30, 2021
Primary CompletionJan 20, 2023
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 5.9 years ago
Interventions
Pneumovax 23- pneumococcal polysaccharidebiological
PPSV23 is a vaccine to help protect against serious infection due to the Streptococcus pneumoniae bacteria. One dose administered intramuscularly or subcutaneously.
Blood drawprocedure
6 ml blood draw at baseline and 6 months post immunization